https://t.co/52TTzXVGSe 💛 Grateful to the @AlexsLemonade Foundation for supporting our fight against childhood brain tumors. Their commitment to funding high-risk, high-reward research is helping us uncover new treatments for adamantinomatous craniopharyngioma (ACP) and improve

As we say, here, it's different! So proud to be: Top 10 in the nation  No. 1 in Colorado and the region

So happy to reconnect and so proud to be part of AARN. It’s been an incredible journey seeing how we support each other and collaborate. Together, we can do great research and defeat brain tumors. 💪 @theABTA #AARN2025 @TerasakiInst

NBTS is disappointed that the NCI won’t be renewing its funding for the Pediatric Brain Tumor Consortium (PBTC) in 2026. Read more about this decision, what we learned after many conversations with stakeholders, and why we disagree with the outcome: https://t.co/k7rAWt2SB7

… and that’s a wrap! Great #AARN2025 @theABTA annual meeting, congrats Will and @ZhaohuiWang5 on putting together an exceptional program! Great to see so many friends and colleagues, looking forward to continued collaborations! #BTSM

The Desi’s at #AARN2025 @theABTA FANTASTIC representation by Indian origin scientists at the ABTA. @JustinLathia

#AARN2025 #ABTA @theABTA the phenomenal network at the American brain tumor Association.

Great AM session on why immunotherapy fails with @d_bayik @florisbarthel @dwainwright_PhD at the #AARN2025 @theABTA meeting! Lots to think about on how to harness the power of immunotherapy in #GBM #ABTAResearcher

New #JITC article: Differential phagocytosis induces diverse macrophage activation states in malignant gliomas https://t.co/74jekdTLGr

Huge shoutout to Senthil Laxmanna Chetty for leading this work 📷 and deepest thanks to the B+ Foundation, @MorganAdamsFdn @CancerLeagueCO @CUCancerCenter for their incredible support.

The takeaway? Phagocytosis isn’t just garbage disposal; it’s a full metabolic and functional makeover, depending on what’s on the macrophage’s menu. This opens new doors for reprogramming innate immunity in brain tumors and beyond.

CD47-blocked “diners” rev up their metabolism for efficient antigen presentation. The real treat comes when you combine both—macrophages adopt a hybrid, super-charged state that drives stronger anti-tumor immunity and, in mouse models, even shrinks gliomas and prolongs survival.

We found that radiation and CD47 blockade not only make glioma cells tastier for macrophages, but also imprint distinct fates. Radiation-fed macrophages crank up inflammatory and interferon-gamma pathways,

Spoiler alert: nope, the aftermath is very different. Just like our post-meal states range from couch-potato coma to energetic glow, macrophages also get reprogrammed by what they ingest.

Finally answering a burning question: do macrophages feel the same after “eating” a tumor cell as we do after a bean burrito vs. a kale salad? Differential phagocytosis induces diverse macrophage activation states in malignant gliomas